

19 July 2022

Arthritis and Dermatology pharma

- 1. In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?**

The information requested is not collated centrally and an extensive trawl of patient records would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

- 2. Of these five, how many of each received the following products:**

Total number of Arthritis patients treated in the last 4 months as follows

Abatacept	28
Adalimumab (Humira)	219
Amgevita	4
Apremilast	30
Baracitinib	28
Benepali (Etanercept)	199
Certolizumab (Cimzia)	72
Etanercept (Enbrel)	61
Golimumab	63
Guselkumab	5
Imraldi (Adalimumab)	375
Infliximab (Remicade)	20
Remsima (Infliximab)	16
Rituximab	20
Sarilumab	3
Seckukinumab	137
subcut Abatacept	54
Sub-cut Tocilizumab	48
Taltz (Ixekizumab)	52

19 July 2022

Tocilizumab	15
Tofacitanib	10
Truxima	99
Upadacitinib	22
Ustekinumab	9

Response from Dermatology Service:

	Psoriasis	HS
- Adalimumab (Humira)	28	16
- Adalimumab Biosimilar	152	17
- Etanercept (Enbrel)	0	0
- Etanercept Biosimilar	8	0
- Infliximab (Remicade)	< 5	< 5
- Infliximab biosimilar	< 5	7
- Golimumab (Simponi)	0	0
- Tofacitinib (Xeljanz)	0	0
- Ustekinumab (Stelara)	79	< 5
- Vedolizumab(Entyvio)	0	0
- Filgotinib (Jyseleca)	0	0
- Abatacept (Orencia)	0	0
- Baricitinib (Olumiant)	0	0
- Certolizumab Pegol (Cimzia)	< 5	0
- Rituximab (MabThera)	0	0
- Rituximab Biosimilar	0	0
- Tocilizumab (RoActemra)	0	0
- Sarilumab (Kevzara)	0	0
- Apremilast (Otezla)	8	0
- Secukinumab (Cosentyx)	37	0
- Isekizumab (Taltz)	49	0
- Guselkumab (Tremfya)	83	0
- Brodalumab (Kyntheum)	< 5	0
- Risankizumab (Skyrizi)	62	0
- Tildrakizumab (Ilumetri)	6	0
- Upadacitinib (Rinvoq)	0	0
- Bimekizumab (Bimzelx)	< 5	0

Please note:

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

3. Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

This is not applicable to Rheumatology nor Dermatology

19 July 2022

4. Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- AxSPA
- PsA
- PsO

Patients may be treated with Disease-modifying anti-rheumatic drugs (DMARDs) prior to commencement of biologic drugs. The number of patients treated with DMARDs by condition is not collated centrally and an extensive trawl of patient records would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.